Navigation Links
Nektar Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/2/2011

p>

(3,388)(4,989)Other assets

(1,750)1Accounts payable

(4,200)1,755Accrued compensation

2,508500Accrued expenses

6,2384,090Accrued clinical trial expenses

1,468(1,408)Deferred revenue

(12,320)(83,107)Other liabilities

(2,681)(2,049)Net cash used in operating activities

$   (71,528)$ (76,278)Cash flows from investing activities:Purchases of investments

(627,529)(315,160)Sales of investments

218,66010,290Maturities of investments

290,810360,906Purchases of property and equipment

(8,294)(22,160)Net cash (used in) provided by investing activities

$ (126,353)$  33,876Cash flows from financing activities:Payments of loan and capital lease obligations

(1,431)(1,119)Issuance of common stock, net of issuance costs

224,0727,142Net cash provided by financing activities

$  222,641$
,023Effect of exchange rates on cash and cash equivalents

493(312)Net increase (decrease) in cash and cash equivalents

$
25,253$ (36,691)Cash and cash equivalents at beginning of period

17,75549,597Cash and cash equivalents at end of period

$
43,008$  12,906
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... 2014) Doctors who treat patients with a ... can face an agonizing treatment decision. , The ... and help relieve shortness of breath. But some ... can cause potentially fatal complications following transplantation. , ... Dilling, medical director of Loyola University Medical Center,s ...
(Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... Elderly People Suffering From CHF, COPD, Diabetes and, ... More Effective With a New, Interactive Telehealth ... NOERRESUNDBY, Denmark, May 19 RTX Healthcare,today announced ... telehealth,monitors, which allows healthcare system integrators and disease ...
... now available in Lexi-Comp(R) ONLINE(TM), providing ... information on diseases and disorders, ... leading,provider of drug reference information, now offers Harrison,s Practice, ... conditions. Harrison,s Practice, developed by McGraw-Hill,Professional, a leading global ...
... United States today are now much more likely to be ... of kidney cancer than a decade ago, leading to a ... national study led by a UC San Diego Medical Center ... UC San Diego Medical Center and the Moores UCSD Cancer ...
... Many patients may soon find relief from the ... bowel syndrome, or IBS. , Lubiprostone, known by the ... Food and Drug Administration for use in women with ... Michigan Health System research that demonstrated the safety and ...
... to advance, device enables deeper enteroscopy, SAN ... ), a leading developer of diagnostic and therapeutic,advancement ... Week 2008 that it has received 510(k) clearance ... with its Endo-Ease Discovery SB,device in endoscopic procedures., ...
... openings avoids incisions, shortens recoveries , , SUNDAY, May ... may lead to painless and scar-free surgery with ... laparoscopic surgery, U.S. studies suggest. , Called ... is inserted through a natural body opening, rather ...
Cached Medicine News:Health News:RTX Healthcare Launch Wireless Telehealth Monitor With Built-in GSM/GPRS Mobile Phone Technology 2Health News:Lexi-Comp, Inc. Offers Diagnosis and Disease Management Tool 2Health News:Lexi-Comp, Inc. Offers Diagnosis and Disease Management Tool 3Health News:Majority of kidney cancers diagnosed at earliest stage 2Health News:Drug brings relief for many IBS patients who experience constipation 2Health News:Spirus Medical Announces 510(k) Clearance from FDA for Expanded Use of Endo-Ease(R) Discovery SB(TM) 2Health News:New Surgical Technology Holds Promise of Painless, Scarless Procedures 2Health News:New Surgical Technology Holds Promise of Painless, Scarless Procedures 3
... neurophysiological monitoring system has been designed ... the needs of the ever changing ... collection and analyzing data from multiple ... EMG, EEG and multiple patients at ...
... Inc. is the largest independently ... to ophthalmic surgical instrumentation. Katena ... 7,000 customers in the United ... network of distributors, to customers ...
... Studies have proven that the management of diabetes ... glucose levels is the most effective way to ... care aimed at maintaining or improving a diabetes ... and costly. , ,These have been the ...
... is intended for detecting trends and tracking ... 18 and older) and children/adolescents (aged 7 ... the use of the G2 Biographer with ... to supplement, not replace, conventional blood glucose ...
Medicine Products: